TY - JOUR
T1 - A European pharmacotherapeutic agent roflumilast exploring integrated preclinical and clinical evidence for SARS CoV-2 mediated inflammation to organ damage
AU - Singh, Yogendra
AU - Fuloria, Neeraj Kumar
AU - Fuloria, Shivkanya
AU - Subramaniyan, Vetriselvan
AU - Almalki, Waleed Hassan
AU - Al-abbasi, Fahad A.
AU - Kazmi, Imran
AU - Rajput, Sobhit Singh
AU - Joshi, Nirmal
AU - Gupta, Gaurav
N1 - Funding Information:
There was no specific funding for this study.
Publisher Copyright:
© 2022 British Pharmacological Society.
PY - 2022/8
Y1 - 2022/8
N2 - COVID-19 has spread globally, affecting almost 160 million individuals. Elderly and pre-existing patients (such as diabetes, heart disease and asthma) seem more susceptible to severe illness with COVID-19. Roflumilast was licensed for usage in the European Union in July 2010 as a phosphodiesterase-4 (PDE4) inhibitor. Under preclinical studies, roflumilast has been shown to decrease bleomycin-induced lung fibrosis, lung hydroxyproline and right heart thickening. The current study reviewed existing data that the PDE-4 inhibitor, a roflumilast, protects renal tissues and other major organ systems after COVID-19 infection by decreasing immune cell infiltration. These immune-balancing effects of roflumilast were related to a decrease in oxidative and inflammatory burden, caspase-3 suppression and increased protein kinase A (PKA)/cyclic A.M.P. (cAMP) levels in renal and other organ tissue.
AB - COVID-19 has spread globally, affecting almost 160 million individuals. Elderly and pre-existing patients (such as diabetes, heart disease and asthma) seem more susceptible to severe illness with COVID-19. Roflumilast was licensed for usage in the European Union in July 2010 as a phosphodiesterase-4 (PDE4) inhibitor. Under preclinical studies, roflumilast has been shown to decrease bleomycin-induced lung fibrosis, lung hydroxyproline and right heart thickening. The current study reviewed existing data that the PDE-4 inhibitor, a roflumilast, protects renal tissues and other major organ systems after COVID-19 infection by decreasing immune cell infiltration. These immune-balancing effects of roflumilast were related to a decrease in oxidative and inflammatory burden, caspase-3 suppression and increased protein kinase A (PKA)/cyclic A.M.P. (cAMP) levels in renal and other organ tissue.
KW - COVID-19
KW - kidney injury
KW - PDE-4 inhibitor
KW - Roflumilast
KW - tumour necrosis factor-alpha
UR - http://www.scopus.com/inward/record.url?scp=85127521230&partnerID=8YFLogxK
U2 - 10.1111/bcp.15328
DO - 10.1111/bcp.15328
M3 - Comment / Debate
C2 - 35352842
AN - SCOPUS:85127521230
SN - 0306-5251
VL - 88
SP - 3562
EP - 3565
JO - British Journal of Clinical Pharmacology
JF - British Journal of Clinical Pharmacology
IS - 8
ER -
